Mei B.
About Mei B.
Mei B. is the Senior Director of Finance and Corporate Controller at Precision BioSciences, Inc., where she has held various finance roles since 2019. She has extensive experience in corporate communications, investor relations, and SEC financial reporting, and is a CPA certified professional.
Current Role at Precision BioSciences
Mei B. serves as the Senior Director of Finance and Corporate Controller at Precision BioSciences, Inc. since September 2023. In this role, she oversees financial operations and reporting, ensuring compliance with SEC regulations for publicly-traded companies. Mei has been an integral part of the Senior Leadership Team, contributing to strategic financial decisions and corporate governance.
Previous Experience at Precision BioSciences
Prior to her current position, Mei held several roles at Precision BioSciences, Inc. She worked as Director of Investor Relations and Finance from 2022 to 2023, and as Director of Financial Reporting from 2021 to 2022. Additionally, she served as Senior Manager of Financial Reporting and Associate Director of Financial Reporting, gaining extensive experience in financial management and reporting within the biotechnology sector.
Background in Finance and Accounting
Mei B. has a strong background in finance and accounting, beginning her career as a Staff Auditor at Cherry, Bekaert & Holland from 2008 to 2009. She then worked as an Accounting Manager at the Institute for Defense and Business from 2009 to 2014, followed by a role as Senior Accountant at Cempra Pharmaceuticals, Inc. from 2014 to 2017. She also served as Assistant Controller at Heat Biologics from 2017 to 2019.
Education and Professional Certification
Mei holds a Bachelor of Science in Business Administration (BSBA) with a focus on Accounting from West Virginia University, where she studied from 2003 to 2007. She is a Certified Public Accountant (CPA), which underscores her expertise in financial reporting and compliance.
Expertise in Investor Relations
Mei B. specializes in corporate communications and investor relations, actively engaging in activities that enhance stakeholder communication. She was involved in Precision's 2023 In Vivo R&D Day, showcasing her commitment to fostering relationships with investors and ensuring transparency in financial reporting.